CD33 and acute myeloid leukemia: Targeted gene insertion into a safe-harbor locus via homologous repair using CRISPR/Cas9 gene editing in combination with adeno-associated virus (AAV)-mediated gene delivery was used to generate primary CD33 CAR-NK cells with confirmation of enhanced anti-AML activity (198).